Inspired by the million people in the UK living with undiagnosed diabetes, the team of six WBS colleagues conceptualized a non-invasive test that will help people find out quickly and easily if they have the disease, read more one the foundations of the startup here
GlucoLive is developing a non-invasive method of screening for Type 2 diabetes. There are around 1 million people in the UK with undiagnosed Type-2 diabetes, which if left untreated can lead to irreversible health complications. Worldwide, it is estimated that 1 in 2 people with diabetes are currently undiagnosed (approximately 460 million people).
At present, 1 in 3 patients will have health complications by the time they are diagnosed with Type 2 diabetes. Although some countries have screening programmes in place, these often miss at risk groups for lots of reasons, including the need for invasive blood tests, the subtle nature of the symptoms of diabetes, and people’s desire to avoid seeing a doctor. GlucoLive’s device allows people to test themselves for diabetes in a non-invasive and non-threatening way, and empowers them to engage with health services for further testing.
The benefits of GlucoLive’s innovative method of screening are far reaching. People will be empowered to take charge of their own health, leading to more engaged patients, better long-term health and quality of life. There will also be a reduction in the financial impact on the health sector – currently around £10 billion is spent per year on diabetes related complications – and in the long term vital hospital bed space will be freed up as the number of patients in hospital due to complications of diabetes reduces. The screening method also has the ability to provide businesses and workplaces with a way to demonstrate their social responsibility towards employees and customers. For further information click here